Induced pluripotent stem cells as platforms for engineering NK cell immunotherapies
Frontiers in Cell and Developmental Biology · 01.05.2026 · 14
DOI: 10.3389/fcell.2026.1810206 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Cell and Developmental Biology, online erschienen am 01.05.2026. Verfasst von Anna Jezierski und 5 weiteren Autor:innen. Beteiligte Einrichtung: Human Health Therapeutics Research Center, Translational Biosciences, National Research Council of Canada, Ottawa, ON, Canada. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 96 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Human induced pluripotent stem cells (iPSCs) are transforming adoptive cell therapy by combining unlimited self-renewal, broad differentiation potential, and high amenability to genome engineering. These attributes make iPSCs a versatile source for the development of standardized immune effector cells at industrial scale, enabling a shift from patient- or donor-restricted cell products toward true off-the-shelf immunotherapies that can be improved through iterative genome engineering. iPSC-derived natural killer (iNK) cells are the most clinically advanced and exemplify the platform’s advantages over conventional autologous or donor-sourced approaches. Unlike autologous therapies, which require labor-intensive and expensive personalized clinical-grade manufacturing, and are constrained by variable quality and genetic intractability of donor products, iPSC technology supports the creation of renewable, clonally defined master cell banks as uniform starting material for NK-cell therapy products. Advances in CRISPR/Cas-based editing now permit multiplex introduction of functional traits, enhanced cytokine signaling, antibody-dependent cytotoxicity, checkpoint resistance, optimized trafficking, safety switches, and increasing signal complexity, directly at the pluripotent or progenitor stages; ultimately allowing for fully-programmable iNK cells with customizable potency and persistence. Early clinical studies of iNK products validate the feasibility, safety, and therapeutic potential of this approach, but also underscore the need for continued refinement of differentiation protocols, manufacturing pipelines, and regulatory standards to ensure efficacy, genomic stability, phenotypic maturity, and long-term safety. This review outlines current breakthroughs and future directions of iNK cell therapies, emphasizing how programmable iPSC chassis platforms are enabling modular and off-the-shelf targeted immunotherapies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Human Health Therapeutics Research Center, Translational Biosciences, National Research Council of Canada, Ottawa, ON, Canada.
- Ottawa Institute of Systems Biology, University of Ottawa, Ottawa, ON, Canada.
- Department of Biochemistry, Microbiology and Immunology, Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada.
- Centre de Recherche du CHU Ste-Justine, Montréal, QC, Canada.
- Département de Pharmacologie et Physiologie, Université de Montréal, Montréal, QC, Canada.
Zitieren
APA
Jezierski, A., Huang, J., Desbiens, L., Benabdallah, B., McComb, S., & Beausejour, C. (2026). Induced pluripotent stem cells as platforms for engineering NK cell immunotherapies. Frontiers in Cell and Developmental Biology, 14. https://doi.org/10.3389/fcell.2026.1810206
Vancouver
Jezierski A, Huang J, Desbiens L, Benabdallah B, McComb S, Beausejour C. Induced pluripotent stem cells as platforms for engineering NK cell immunotherapies. Frontiers in Cell and Developmental Biology. 2026;14. doi:10.3389/fcell.2026.1810206
BibTeX
@article{Jezierski2026,
author = {Jezierski, Anna and Huang, Jez and Desbiens, Lea and Benabdallah, Basma and McComb, Scott and Beausejour, Christian},
title = {Induced pluripotent stem cells as platforms for engineering NK cell immunotherapies},
journal = {Frontiers in Cell and Developmental Biology},
year = {2026},
volume = {14},
doi = {10.3389/fcell.2026.1810206}
}
EUVIMED